There's an interesting story playing out with shares of Retrophin (RTRX +28.9%), which are up sharply in morning trading.
The company priced a 4.7M share offering at $8.50 for gross proceeds of $40M.
In connection, RTRX announces approval to list on the NASDAQ Global Market. (PR)
In what has been deemed at shot at Questcor (QCOR +0.5%), RTRX is developing RE-034 for the treatment of Infantile Spasms.
Additionally, there have been some rather interesting comments emanating from what is purportedly the CEO's twitter account. On the offering: "I'm just going to type up a form letter for investors who are angry at me that they didn't get any [stock] in the offering." On QCOR (from Wednesday): "We filed an antitrust lawsuit against QCOR in California last night."